Effects of etomidate combined with dexmedetomidine on adrenocortical function in elderly patients: a double-blind randomized controlled trial

Fangjun Wang1*, Zheng Yang2, Sisi Zeng2, Luyue Gao2, Jiabei Li2 & Na Wang2

Etomidate has been advocated to be used in anesthesia for the elderly and the critically ill patients due to its faint effect on cardiovascular system. But the dose-dependent suppression of etomidate on adrenal cortex function leads to the limitation of its clinical application. Clinical research showed that dexmedetomidine could reduce the dose requirements for intravenous or inhalation anesthetics and opioids, and the hemodynamics was more stable during the operation. The objective was to observe the effect of etomidate combined with dexmedetomidine on adrenocortical function in elderly patients. 180 elderly patients scheduled for elective ureteroscopic holmium laser lithotripsy were randomly allocated to PR group anesthetized with propofol-remifentanil, ER group anesthetized with etomidate-remifentanil, and ERD group anesthetized with dexmedetomidine combined with etomidate-remifentanil. Patients in each group whose operation time was less than or equal to 1 h were incorporated into short time surgery group (PR1 group, ER1 group and ERD1 group), and whose surgical procedure time was more than 1 h were incorporated into long time surgery group (PR2 group, ER2 group and ERD2 group). The primary outcome was the serum cortisol and ACTH concentration. The secondary outcomes were the values of SBP, DBP, HR and SpO2, the time of surgical procedure, the dosage of etomidate and remifentanil administered during surgery, the time to spontaneous respiration, recovery and extubation, and the duration of stay in the PACU. The Serum cortisol concentration was higher at t1~2 in ERD1 group compared to ER1 group (P < 0.05). The Serum cortisol concentration at t1~3 was higher in ERD2 group than in ER2 group (P < 0.05). The Serum ACTH concentration was lower at t1~2 in ERD1 group compared to ER1 group (P < 0.05). The Serum ACTH concentration at t1~3 was lower in ERD2 group compared to ER2 group (P < 0.05). The SBP at T1 and T3 were higher in ER2 and ERD2 group than in PR2 group (P < 0.05). The DBP in ER1 and ERD1 group were higher at T1 compared to PR1 group (P < 0.05). The dosage of etomidate was significantly lower in ERD1 group and ERD2 group than in ER1 group and ER2 group (P < 0.05), respectively. The administration of dexmedetomidine combined with etomidate can attenuate the inhibition of etomidate on adrenocortical function in elderly patients and maintain intraoperative hemodynamic stability.

Etomidate is a short acting intravenous general anaesthetic derived from imidazole, which shows better sedative effect and no analgesic effect. The drug has been advocated to be used in anesthesia for the elderly and the critically ill patients due to its faint effect on cardiovascular system. The adrenocortical function of the patients anesthetized with etomidate was suppressed, and it was dose-dependent1,2. Dexmedetomidine is a highly effective and selective α2-adrenergic receptor agonist, which manifests the effects of sedation, analgesia, anti-anxiety and sympathetic inhibition in a dose-dependent manner, with few side effects. At present, clinical research shows that dexmedetomidine can reduce the dose requirements for intravenous or inhalation anesthetics and opioids, and the hemodynamics is more stable during the operation3–5. However, there is no report on the effect of etomidate combined with dexmedetomidine on adrenocortical function in elderly patients. We hypothesized that dexmedetomidine could reduce the intraoperative dose requirements for etomidate, and the inhibition of

1The Affiliated Hospital of North Sichuan Medical College, Nanchong, China. 2The North Sichuan Medical College, Nanchong, China. *email: wfjlxy006@nsmc.edu.cn
adrenocortical function is also attenuated with the decrease in the dose of etomidate. Therefore, the aim of this study was to observe the effect of etomidate combined with dexmedetomidine on adrenocortical function in elderly patients.

Methods

This study received approval from the Ethics Committee of the affiliated hospital of north sichuan medical college, Sichuan, China (Ref. 2018ER(R)008) in March 2018 and was registered at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/; Registration number: ChiCTR180015421, 29/03/2018). All participants provided written informed consent before participation. Patients scheduled for elective ureteroscopic holmium laser lithotripsy were enrolled. The inclusion criteria were age ≥ 60 years old, American Society of Anaesthesiologists physical status 1 or 2, a diagnosis of kidney or ureteral calculi. The exclusion criteria were as follows: severe functional liver or kidney disease, Cognitive dysfunction (performance < 26 points on a Montreal Cognitive Assessment), abnormal state of consciousness (including sleepiness, mental confusion, lethargic sleep and comatose), with a medical history of steroid therapy, with an endocrine disease. Withdrawal criteria: patients refusing to participate, change of surgical plan, incomplete data collection.

All patients enrolled were randomly divided into three groups, using sealed envelopes indicating the allocation, to receive intravenous anesthesia with propofol-remifentanil (PR group, n = 60), etomidate-remifentanil (ER group, n = 60) and etomidate-remifentanil combined with dexmedetomidine (ERD group, n = 60). Randomization was done by using the random number table, 180 three-digit numbers selected randomly from the random number table were serialized from small to large, then the serial numbers 1–60 were set as PR group, 61–120 as ER group and 121–180 as ERD group. All cards identifying patient grouping information were sealed in opaque envelopes. Randomization was performed by an anesthesiologist who was not responsible for surgical anesthesia of the patients or data collection. The anaesthesia nurses prepared the dexmedetomidine or saline according to the concealed envelope for random allocation. Patients in each group whose operation time was less than or equal to 1 h were incorporated into short time surgery group (PR group, ER group, and ERD group), and whose operation time was more than 1 h were incorporated into long time surgery group (PR group, ER group and ERD group). The participating patients, surgeons, nurses and anaesthetists were blinded to the treatment allocation.

Patients were routine monitored with electrocardiography, noninvasive blood pressure (systolic blood pressure, mean arterial pressure and diastolic blood pressure), heart rate, respiratory rate, pulse oximetry, end-tidal CO2, the bispectral index and temperature upon arrival at the operating room. The 6 l/min oxygen was provided to all patients by a facemask. After a good upper extremity IV access secured, anaesthesia was induced with intravenous injection of midazolam 0.04 mg/Kg, propofol 1.5 mg/Kg, remifentanil 2 μg/Kg, cis-atracurium 0.2 mg/Kg in PR group, and midazolam 0.04 mg/Kg, etomidate 0.3 mg/Kg, remifentanil 2 μg/Kg, cis-atracurium 0.2 mg/Kg in ER group and ERD group. Controlled mechanical ventilation was adjusted to maintain an end-tidal carbon dioxide concentration of 35 to 45 mmHg after endotracheal tube insertion. Anaesthesia was maintained according to a BIS value of 40 to 60 with propofol plasma target concentration of 2 to 3 μg/ml and remifentanil plasma target concentration of 4 to 6 ng/ml in PR group, and etomidate plasma target concentration of 4 to 6 μg/ml and remifentanil plasma target concentration of 4 to 6 ng/ml in ER group and ERD group. Dexmedetomidine 0.4 μg/kg/h was administered immediately after induction of anesthesia in ERD group, and equal volume of normal saline was administered in the other groups. Cis-atracurium and dexmedetomidine were stopped 45 min and 20 min before the end of the operation, respectively. Propofol, etomidate and remifentanil were stopped five minutes before the end of the operation. The patients were extubated after spontaneous respiration (tidal volume > 6 ml/kg, respiratory rate > 13/min, SpO2 > 90% under air inspiration, BIS > 80, and a train-of-four (TOF) ratio ≥ 0.9. Patients were transferred to the post-anesthesia care unit (PACU) after extubation, and when the modified Aldrete score > 9, the patients were transferred to the surgical ward. Hypotension (defined as systolic falling more than 20% before anesthesia or systolic values lower than 80 mmHg) was treated with epinephrine 6 mg intravenous bolus immediately. Bradycardia (defined as heart < 55 beats/minute) was treated with 0.5 mg of injection atropine.

6 ml venous blood of the patients was taken 15 min before anesthesia induction (t0), 6 h (t1), 12 h (t2), 24 h (t3), 48 h (t4) and 72 h (t5) after anesthesia respectively, all the blood samples were centrifugated at 3000 r/min for 5 min, 2 ml of serum of each sample was taken and stored at –80 °C in refrigerator for detection later. The serum cortisol concentration was measured by electrochemiluminescence (ECL)3, and plasma adrenocorticotropic hormone (ACTH) was determined by radioimmunoassay4. The values of SBP, DBP, HR and SpO2 were recorded 5 min before anesthesia induction (t0), 5 min after anesthesia induction (t1), at the beginning of surgery (t2), during surgery (t3), 6 h after surgery (t4), 12 h after surgery (t5), 24 h after surgery (t6) and 48 h after surgery (t7). The time of surgical procedure, the dosage of etomidate and remifentanil administered during surgery, the time to spontaneous respiration, recovery and extubation (time from stopping administration of propofol or etomidate to spontaneous respiration, recovery and extubation respectively), and the duration of stay in the PACU were recorded.

Statistical analysis. Statistical analyses were carried out using SPSS 19.0. Previous study found that 24 h after administration of etomidate, the plasma cortisol concentration of patients decreased about 4 μg/dl 5. In order to detect a difference of at least 2ug/dl in serum cortisol concentration between the two study groups with 90% power and 5% probability of type 1 error, this calculation assumed an SD of 2.2 in the serum cortisol concentration. 27 subjects were required per group. To account for a 10% dropout rate, 30 elderly patients in each group were recruited. The following formulas were used to compute the sample size:

\[ n = \left( \frac{Z_{\alpha/2} \cdot \sigma}{\Delta} \right)^2 \]

where

- \( n \) is the sample size
- \( Z_{\alpha/2} \) is the standard normal deviate corresponding to the desired confidence level (1.96 for 95% confidence)
- \( \sigma \) is the standard deviation of the population
- \( \Delta \) is the smallest difference we are willing to detect
Assess for eligibility \( (n=180) \)

Randomized \( (n=180) \)

- Allocated to PR group \( (n=60) \)
  - surgery time \( \leq 1 \text{h} \), incorporated into PR\(_1\) group \( (n=28) \)
  - Analysed \( (n=28) \)
  - Excluded from analysis \( (n=0) \)

- Allocated to ER group \( (n=60) \)
  - surgery time \( > 1 \text{h} \), incorporated into PR\(_2\) group \( (n=32) \)
  - Analysed \( (n=32) \)
  - Excluded from analysis \( (n=0) \)

- Allocated to ERD group \( (n=60) \)
  - surgery time \( \leq 1 \text{h} \), incorporated into ER\(_1\) group \( (n=29) \)
  - Analysed \( (n=29) \)
  - Excluded from analysis \( (n=0) \)

  - surgery time \( > 1 \text{h} \), incorporated into ER\(_2\) group \( (n=31) \)
  - Analysed \( (n=31) \)
  - Excluded from analysis \( (n=0) \)

  - surgery time \( \leq 1 \text{h} \), incorporated into ERD\(_1\) group \( (n=32) \)
  - Analysed \( (n=32) \)
  - Excluded from analysis \( (n=0) \)

  - surgery time \( > 1 \text{h} \), incorporated into ERD\(_2\) group \( (n=28) \)
  - Analysed \( (n=28) \)
  - Excluded from analysis \( (n=0) \)

**Figure 1.** One hundred and eighty patients were screened for eligibility, and subsequently allocated to three groups. No patient dropped out of the trial. A total of one hundred and eighty patients completed the study (in this figure).

\[
n = \frac{(z_\alpha + z_\beta)^2 \cdot 2\sigma^2}{\delta^2}
\]

\( \sigma \) stands for standard deviation and \( \delta \) represents the difference of the means.

Quantitative variables were expressed as mean \( \pm \) standard deviation (SD), enumeration data was presented as frequencies. Comparison of the demographic data and clinical characteristics of the six groups were made using the Student’s t-test, Mann–Whitney \( U \) test and \( \chi^2 \) test as appropriate. Repeated measures analysis of variance was used for comparisons of SBP, DBP, HR, serum cortisol and ACTH concentration levels among groups at each time point, if comparison between groups was positive, the SNK post hoc test was performed. The statistical significance was determined as \( p < 0.05 \).

**Statement of ethics.** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Following the approval by the Ethics Committee of the affiliated hospital of north Sichuan Medical College (Ref. 2018ER(R)008), we obtained the written informed consent from all the participants for this randomized prospective clinical trial conducted at the affiliated hospital of north sichuan medical college, on patients with kidney or ureteral calculi.

**Results**

One hundred and eighty patients were screened for eligibility, and subsequently allocated to three groups. No patient dropped out of the trial. A total of one hundred and eighty patients completed the study (shown in Fig. 1).

There were no differences in age, weight, ASA grade and sex ratio among patients in each group (shown in Tables 1 and 2).

The Serum cortisol concentration was lower at \( t_{1-2} \) in ER\(_1\) group and \( t_1 \) in ERD\(_1\) group compared to \( t_0 \) and PR\(_1\) group \( (P<0.05) \). The Serum cortisol concentration at \( t_{1-2} \) was higher in ERD\(_2\) group than in ER\(_1\) group \( (P<0.05) \), (shown in Fig. 2). The Serum cortisol concentration was lower at \( t_{1-3} \) in ER\(_2\) group and \( t_{1-2} \) in ERD\(_2\) group.

\[\text{Assess for eligibility (n=180)}\]

Randomized (n=180)

- Allocated to PR group (n=60)
  - surgery time \( \leq 1h \), incorporated into PR\(_1\) group (n=28)
  - Analysed (n=28)
  - Excluded from analysis (n=0)

- Allocated to ER group (n=60)
  - surgery time \( > 1h \), incorporated into PR\(_2\) group (n=32)
  - Analysed (n=32)
  - Excluded from analysis (n=0)

- Allocated to ERD group (n=60)
  - surgery time \( \leq 1h \), incorporated into ER\(_1\) group (n=29)
  - Analysed (n=29)
  - Excluded from analysis (n=0)

  - surgery time \( > 1h \), incorporated into ER\(_2\) group (n=31)
  - Analysed (n=31)
  - Excluded from analysis (n=0)

  - surgery time \( \leq 1h \), incorporated into ERD\(_1\) group (n=32)
  - Analysed (n=32)
  - Excluded from analysis (n=0)

  - surgery time \( > 1h \), incorporated into ERD\(_2\) group (n=28)
  - Analysed (n=28)
  - Excluded from analysis (n=0)
The Serum cortisol concentration at t1~3 was higher in ERD2 group compared to t0 and PR2 group (P < 0.05). The Serum cortisol concentration at t1~2 was higher in ERD1 group compared to ER1 group (P < 0.05), (shown in Fig. 3).

The Serum ACTH concentration was higher at t1~2 in ER1 group and t1 in ERD1 group compared to t0 and PR1 group (P < 0.05). The Serum ACTH concentration at t1~2 was lower in ERD1 group than in ER1 group (P < 0.05), (shown in Fig. 4). The Serum ACTH concentration was higher at t1~3 in ER2 group and t1~2 in ERD2 group compared to t0 and PR2 group (P < 0.05). The Serum ACTH concentration at t1~3 was lower in ERD2 group than in ER2 group (P < 0.05), (shown in Fig. 5).

Table 1. Demographic data in short operation time groups. The Patient characteristics in short operation time groups are shown in this table. Patient characteristics were similar among the three groups, (in this table). Values are mean ± SD. ASA American Society of Anesthesiologists, PR1 Propofol-remifentanil, ER1 Etomidate-remifentanil, ERD1 Etomidate-remifentanil and dexmedetomidine.

| Patient characteristics | PR1 n=28 | ER1 n=29 | ERD1 n=32 | F/X2 values |
|-------------------------|----------|----------|-----------|-------------|
| Sex (male/female)       | 15/13    | 14/15    | 16/16     | 0.0691      |
| Age (years)             | 66.4 ± 4.6 | 65.6 ± 3.1 | 67.3 ± 4.8 | 1.21        |
| Weight (kg)             | 57.5 ± 5.8 | 56.9 ± 7.1 | 58.0 ± 6.4 | 1.03        |
| ASA (I/II)              | 9/19     | 11/18    | 13/19     | 0.4488      |

Table 2. Demographic data in long operation time groups. The Patient characteristics in long operation time groups are shown in this table. Patient characteristics were similar among the three groups, (in this table). Values are mean ± SD. ASA American Society of Anesthesiologists, PR2 Propofol-remifentanil, ER2 Etomidate-remifentanil, ERD2 Etomidate-remifentanil and dexmedetomidine.

| Patient characteristics | PR2 n=32 | ER2 n=31 | ERD2 n=28 | F/X2 values |
|-------------------------|----------|----------|-----------|-------------|
| Sex (male/female)       | 15/17    | 15/16    | 15/13     | 0.2588      |
| Age (years)             | 65.7 ± 4.0 | 65.2 ± 3.5 | 66.1 ± 3.8 | 0.51        |
| Weight (kg)             | 56.9 ± 7.0 | 56.6 ± 8.8 | 58.7 ± 9.0 | 0.52        |
| ASA (I/II)              | 14/18    | 12/19    | 11/17     | 0.1293      |

Figure 2. The Serum cortisol concentration changes in the short operation time groups at different time points. The Serum cortisol concentration at different time points in short operation time groups are shown in this figure. The Serum cortisol concentration were lower at t1~2 in ER1 group and t1 in ERD1 group compared to t0 and PR1 group (P < 0.05). The Serum cortisol concentration were higher at t1~2 in ERD1 group compared to ER1 group (P < 0.05), (in this figure).
The SBP was lower at T1 compared to T0 in short time surgery groups (P < 0.05). The SBP in ER1 and ERD1 group was higher at T1 and T3 compared to PR1 group (P < 0.05). The SBP at T4 was lower in ERD1 group than in ER1 group (P < 0.05), (shown in Table 3). The SBP was lower at T1 compared to T0 in long time surgery groups (P < 0.05). The SBP in ER2 and ERD2 group were higher at T1 and T3 compared to PR2 group (P < 0.05). The SBP at T4 were lower in ERD2 group than in ER2 group (P < 0.05), (shown in Table 4).

Figure 3. The Serum cortisol concentration changes in the long operation time groups at different time points. The Serum cortisol concentration at different time points in long operation time groups are shown in this figure. The Serum cortisol concentration were lower at t1~3 in ER2 group and t1~2 in ERD2 group compared to t0 and PR2 group (P < 0.05). The Serum cortisol concentration were higher at t1~3 in ERD2 group compared to ER2 group (P < 0.05), (in this figure).

Figure 4. The Serum ACTH concentration changes in the short operation time groups at different time points. The Serum ACTH concentration at different time points in short operation time groups are shown in this figure. The Serum ACTH concentration were higher at t1~2 in ER1 group and t1 in ERD1 group compared to t0 and PR1 group (P < 0.05). The Serum ACTH concentration were lower at t1~2 in ERD1 group compared to ER2 group (P < 0.05), (in this figure).
The DBP was lower at T1 compared to T0 in short time surgery groups (P < 0.05). The DBP in ER1 and ERD1 group was higher at T1 compared to PR1 group (P < 0.05). The DBP at T4 was lower in ERD1 group than in ER1 group (P < 0.05), (shown in Table 5). The DBP was lower at T1 compared to T0 in long time surgery groups (P < 0.05). The DBP in ER1 and ERD1 group was higher at T1 compared to PR1 group (P < 0.05). The DBP at T4 was lower in ERD1 group than in ER1 group (P < 0.05), (shown in Table 6).

The HR was lower at T1 and higher at T4 compared to T0 in short time surgery groups (P < 0.05). The HR in ERD1 group was lower at T1 and T4 compared to PR1 group and ER1 group (P < 0.05), shown in (shown in Table 7). The HR was higher at T1 compared to T0 in long time surgery groups (P < 0.05). The HR was higher at T1 compared to ER1 group in PR1 group and ER1 group, and lower at T4 compared to T0 in ERD1 group (P < 0.05). The HR in ERD1 group was lower at T1 and T4 compared to PR1 group and ER1 group (P < 0.05), (shown in Table 8).

The duration of surgery and the length of stay in the PACU were similar among the three short time surgery groups. There was no difference in remifentanil dosage between the ER1 group and ERD1 group. The dosage of

Table 3. The SBP (mmHg) at T0, T1, T2, T3, T4, T5, T6 and T7 in short operation time groups. The SBP at different time points in short operation time groups are shown in this table. The SBP were lower at T1 compared to T0 in three groups (P < 0.05). The SBP in ER1 and ERD1 group were higher at T1 and T3 compared to PR1 group (P < 0.05). The SBP in ERD1 group were lower at T4 compared to ER1 groups (P < 0.05), (in this table).

| Time points | PR1, n = 28 | ER1, n = 29 | ERD1, n = 32 | F values | P values |
|-------------|-------------|-------------|-------------|----------|----------|
| T0          | 122.6 ± 11.8 | 123.4 ± 9.8 | 121.7 ± 11.7 | 0.22     | 0.8005   |
| T1          | 93.8 ± 8.4** | 105.7 ± 6.7** | 103.0 ± 9.5** | 14.92 | 0.000    |
| T2          | 115.3 ± 10.6* | 116.5 ± 7.4* | 115.0 ± 8.4* | 0.55     | 0.5818   |
| T3          | 122.5 ± 8.0** | 118.6 ± 6.3** | 117.6 ± 9.1** | 4.93     | 0.0095   |
| T4          | 129.1 ± 8.6* | 130.4 ± 10.0* | 124.0 ± 7.0** | 5.2      | 0.0074   |
| T5          | 120.3 ± 7.9  | 123.1 ± 8.9  | 121.2 ± 7.6  | 0.78     | 0.461    |
| T6          | 119.8 ± 9.2  | 122.9 ± 10.4 | 121.7 ± 8.5  | 0.58     | 0.56     |
| T7          | 121.7 ± 12.1 | 124.3 ± 10.3 | 122.6 ± 10.1 | 0.19     | 0.8285   |
| F values    | 119.93       | 60.07       | 50.4         | –        | –        |
| P values    | 0.000        | 0.000       | 0.000        | –        | –        |
respiration, tracheal extubation time and the time to recovery were longer in group ERD1 compared with group
anesthesia, T2 remifentanil and dexmedetomidine, T0 etomidate was significantly lower in ERD1 group compared with ER1 group (P < 0.05). The time to spontaneous respiration, tracheal extubation time and the time to recovery and the PACU stay were increased more significantly in such short surgeries.

### Table 4

| Time points | PR1 n = 32 | ER1 n = 31 | ERD1 n = 28 | F values | P values |
|-------------|------------|------------|-------------|----------|----------|
| T0          | 122.5 ± 9.2 | 121.3 ± 11.4 | 120.6 ± 10.9 | 0.14     | 0.6705   |
| T1          | 95.3 ± 6.8** | 102.8 ± 8.0** | 104.5 ± 9.3** | 11.54    | 0.000    |
| T2          | 115.1 ± 7.9* | 118.3 ± 8.4 | 116.1 ± 9.8 | 1.09     | 0.3416   |
| T3          | 113.5 ± 8.1* | 120.0 ± 8.5* | 118.2 ± 10.1* | 4.77     | 0.0108   |
| T4          | 130.2 ± 8.8* | 128.2 ± 10.4* | 122.6 ± 9.5* | 4.31     | 0.0164   |
| T5          | 120.3 ± 8.0 | 122.1 ± 9.1 | 119.8 ± 7.4 | 0.97     | 0.3817   |
| T6          | 123.0 ± 9.2 | 122.5 ± 9.5 | 118.6 ± 8.0 | 2.14     | 0.1237   |
| T7          | 124.0 ± 8.3 | 120.1 ± 10.3 | 123.2 ± 9.3 | 1.11     | 0.3357   |
| \( F \) values | 48 | 18.4 | 10.65 | - | - |
| \( P \) values | 0.000 | 0.000 | 0.000 | - | - |

The SBP (mmHg) at T0, T1, T2, T3, T4, T5, T6 and T7 in long operation time groups. The SBP at different time points in long operation time groups are shown in this table. The SBP were lower at T1 compared to T0 in three groups (P < 0.05). The SBP in ER1 and ERD1 group were higher at T0 and T1 compared to PR1 group (P < 0.05). The SBP in ERD1 group were lower at T4 compared to ER2 groups (P < 0.05), (in this table). Values are mean ± SD. PR, Propofol-remifentanil, ER1 Etomidate-remifentanil, ERD1 Etomidate-remifentanil and dexmedetomidine, T0 before the induction of anesthesia, T1 5 min after induction of anesthesia, T2 the beginning of operation, T3 during operation, T4 6 h after surgery, T5 12 h after surgery, T6 24 h after surgery, T7 48 h after surgery.* \( p < 0.05 \) vs. T0; # \( p < 0.05 \) vs. PR2 group; ^\( p < 0.05 \) vs. ER1 group.

### Table 5

| Time points | PR1 n = 28 | ER1 n = 31 | ERD1 n = 32 | F values | P values |
|-------------|------------|------------|-------------|----------|----------|
| T0          | 78.4 ± 5.8 | 77.6 ± 6.8 | 76.4 ± 6.8 | 0.76     | 0.4722   |
| T1          | 56.1 ± 5.7** | 68.3 ± 9.8** | 67.1 ± 9.8** | 24.92    | 0.000    |
| T2          | 76.9 ± 6.8 | 77.1 ± 5.9 | 77.9 ± 6.3 | 0.29     | 0.7491   |
| T3          | 75.7 ± 6.7 | 78.2 ± 6.3 | 76.5 ± 7.1 | 1.19     | 0.3078   |
| T4          | 85.1 ± 6.1* | 84.9 ± 6.9* | 80.9 ± 7.9* | 4.22     | 0.0266   |
| T5          | 78.7 ± 7.8 | 77.6 ± 6.4 | 78.3 ± 8.1 | 0.09     | 0.9135   |
| T6          | 78.9 ± 4.0 | 78.6 ± 5.3 | 76.8 ± 4.2 | 1.68     | 0.1924   |
| T7          | 77.6 ± 4.4 | 77.8 ± 5.7 | 77.3 ± 5.1 | 0.13     | 0.883    |
| \( F \) values | 55.52 | 10.8 | 9.88 | - | - |
| \( P \) values | 0.000 | 0.000 | 0.000 | - | - |

The DBP (mmHg) at T0, T1, T2, T3, T4, T5, T6 and T7 in short operation time groups. The DBP at different time points in short operation time groups are shown in this table. The DBP were lower at T0 in three groups (P < 0.05). The DBP in ER1 and ERD1 group were higher at T0 and T1 compared to PR1 group (P < 0.05). The DBP in ER1 group were lower at T4 compared to ER2 groups (P < 0.05), (in this table). Values are mean ± SD. PR, Propofol-remifentanil, ER1 Etomidate-remifentanil, ERD1 Etomidate-remifentanil and dexmedetomidine, T0 before the induction of anesthesia, T1 5 min after induction of anesthesia, T2 the beginning of operation, T3 during operation, T4 6 h after surgery, T5 12 h after surgery, T6 24 h after surgery, T7 48 h after surgery.* \( p < 0.05 \) vs. T0; # \( p < 0.05 \) vs. PR2 group; ^\( p < 0.05 \) vs. ER1 group.

etomidate was significantly lower in ERD1 group compared with ER1 group (P < 0.05). The time to spontaneous respiration, tracheal extubation time and the time to recovery were longer in group ERD1 compared with group ER1 (P < 0.05), (shown in Table 9). The duration of surgery was similar among the three long time surgery groups. The dosages of remifentanil and etomidate were significantly lower in ERD2 group compared with ER1 group (P < 0.05). The time to spontaneous respiration, tracheal extubation time, the time to recovery and the PACU stay time were increased more significantly in group ERD2 compared with group ER1 (P < 0.05), (shown in Table 10).

### Discussion

In this study, we found that the plasma concentration levels of cortisol and ACTH returned to preoperative levels 24 h and 48 h after surgery in short time surgery group and long time surgery group, respectively. However, after administration of dexmedetomidine 0.4 μg/kg.h, the serum cortisol and ACTH concentrations returned to the preoperative level 12 h after surgery in short time surgery group, and 24 h after surgery in long time surgery group. The blood pressure during both induction of anaesthesia and surgery was more stable when anesthetized with etomidate than propofol, indicating that the elderly patients performed good hemodynamic stability when anesthetized with etomidate. After intravenous administration of dexmedetomidine, the recovery time was increased significantly especially in such short surgeries.
Although etomidate provides rapid onset, rapid recovery and reliable cardiovascular stability, the suppressive effects of etomidate on adrenocortical function limits its clinical application by anesthetists, especially the increased mortality in critically ill patients was potentially due to the adrenal suppressive effects of etomidate. A specific and reversible blockade of the 11α-hydroxylation and 11β-hydroxylation of adrenal steroid synthesis caused by etomidate lead to the decrease of cortisol, corticosterone and aldosterone synthesis. It was found that the serum corticosterone concentration decreased significantly and lasted for more than 3 h after 120 min infusion of etomidate, and returned to pre anesthesia levels 24 h later. The serum cortisol concentration of anesthesia induction, the levels of plasma cortisol were suppressed in the first 6 h after induction by intravenous infusions of etomidate. In this study, etomidate 0.3 mg/kg was used for anesthesia induction and the anesthesia was maintained with intravenous target concentration of etomidate 4 to 6 μg/ml. In the short time surgery group, the serum cortisol level was significantly lower compared to preoperative level at 6 to 12 h after surgery, and there was no significant difference in serum cortisol level between the baseline and 24 h after surgery. The plasma cortisol concentration was decreased more.

### Table 6

| Time points | PR1 n = 28 | ER1 n = 29 | ERD1 n = 32 | F values | P values |
|-------------|------------|------------|-------------|----------|----------|
| T6          | 79.6 ± 4.4 | 78.7 ± 6.5 | 77.3 ± 7.1 | 1.34     | 0.267    |
| T1          | 69.3 ± 5.1*| 67.7 ± 9.1*| 66.5 ± 5.5*| 1.08     | 0.344    |
| T2          | 78.9 ± 6.4 | 77.0 ± 7.3 | 76.1 ± 7.1 | 0.81     | 0.4478   |
| T3          | 77.3 ± 5.7 | 78.4 ± 7.6 | 67.5 ± 6.9*| 22.86    | 0.000    |
| T4          | 84.5 ± 6.2*| 85.3 ± 4.1*| 81.4 ± 5.9*| 5.7      | 0.0048   |
| T5          | 78.5 ± 8.0 | 78.8 ± 5.6 | 78.5 ± 6.7 | 0.25     | 0.777    |
| T6          | 80.1 ± 7.1 | 78.6 ± 4.6 | 79.1 ± 5.2 | 1.3      | 0.2787   |
| T7          | 79.1 ± 5.2 | 77.4 ± 5.1 | 78.4 ± 4.8 | 0.64     | 0.5291   |
| P values    | 0.000      | 0.0001     | 0.000       |           | -        |

### Table 7

| Time points | PR1 n = 28 | ER1 n = 29 | ERD1 n = 32 | F values | P values |
|-------------|------------|------------|-------------|----------|----------|
| T0          | 79.6 ± 4.4 | 78.7 ± 6.5 | 77.3 ± 7.1 | 1.34     | 0.267    |
| T1          | 69.3 ± 5.1*| 67.7 ± 9.1*| 66.5 ± 5.5*| 1.08     | 0.344    |
| T2          | 78.9 ± 6.4 | 77.0 ± 7.3 | 76.1 ± 7.1 | 0.81     | 0.4478   |
| T3          | 77.3 ± 5.7 | 78.4 ± 7.6 | 67.5 ± 6.9*| 22.86    | 0.000    |
| T4          | 84.5 ± 6.2*| 85.3 ± 4.1*| 81.4 ± 5.9*| 5.7      | 0.0048   |
| T5          | 78.5 ± 8.0 | 78.8 ± 5.6 | 78.5 ± 6.7 | 0.25     | 0.777    |
| T6          | 80.1 ± 7.1 | 78.6 ± 4.6 | 79.1 ± 5.2 | 1.3      | 0.2787   |
| T7          | 79.1 ± 5.2 | 77.4 ± 5.1 | 78.4 ± 4.8 | 0.64     | 0.5291   |
| P values    | 0.000      | 0.0001     | 0.000       |           | -        |
Table 8. The HR (beats per minute) at T0, T1, T2, T3, T4, T5, T6 and T7 in long operation time groups. The HR at different time points in long operation time groups are shown in this table. The HR were lower at T1 compared to T0 in three groups \((P<0.05)\). The HR were higher at T4 compared to T0 in PR2 group and ER2 group, and lower at T4 compared to T0 in ERD2 group \((P<0.05)\). The HR in ERD2 group were lower at T3 and T4 compared to PR2 group and ER2 group \((P<0.05)\), (in this table). Values are mean ± SD.

| Time points | PR2 \(n=32\) | ER2 \(n=31\) | ERD2 \(n=28\) | \(F\) values | \(P\) values |
|-------------|---------------|---------------|---------------|--------------|--------------|
| T0          | 78.2 ± 5.6    | 79.1 ± 6.2    | 77.3 ± 4.5    | 0.81         | 0.4491       |
| T1          | 65.7 ± 7.1∗   | 66.3 ± 6.0∗   | 67.8 ± 9.7∗   | 0.64         | 0.5581       |
| T2          | 79.4 ± 6.8    | 78.1 ± 7.8    | 76.7 ± 6.1    | 1.1          | 0.3374       |
| T3          | 77.0 ± 6.3    | 77.1 ± 6.7    | 67.5 ± 5.2∗   | 22.34        | 0.000        |
| T4          | 86.7 ± 4.2∗   | 85.3 ± 5.2∗   | 73.7 ± 7.2∗   | 46.46        | 0.000        |
| T5          | 79.1 ± 5.8    | 79.6 ± 6.9    | 78.6 ± 5.5    | 0.11         | 0.8975       |
| T6          | 78.3 ± 5.4    | 78.5 ± 4.9    | 77.8 ± 6.2    | 0.09         | 0.9168       |
| T7          | 77.5 ± 4.9    | 77.5 ± 4.1    | 78.2 ± 9.1    | 0.13         | 0.8791       |

Table 9. Clinical characteristics in short operation time groups. The clinical characteristics in short operation time groups are shown in this table. The duration of surgery and the length of stay in the PACU were similar among the three groups. There was no difference in remifentanil dosage between the ER1 group and ERD1 group. The dosage of etomidate was significantly lower in ERD1 group compared with ER1 group \((P<0.05)\). The time to spontaneous respiration, tracheal extubation time and the time to recovery were significantly delayed in group ERD1 compared with group ER1 \((P<0.05)\), (in this table). Values are mean ± SD. PR Propofol-remifentanil, ER Etomidate-remifentanil, ERD Etomidate-remifentanil and dexmedetomidine, PACU postanesthesia care unit. ∗\(p<0.05\) vs. PR1 group; †\(p<0.05\) vs. ER1 group.

| Clinical characteristics | PR1 \(n=28\) | ER1 \(n=29\) | ERD1 \(n=32\) | \(F\) values | \(P\) values |
|--------------------------|--------------|--------------|---------------|--------------|--------------|
| Duration of surgery (minute) | 45.9 ± 7.1  | 46.6 ± 5.9  | 47.3 ± 6.1  | 0.11         | 0.8978       |
| Dosage of etomidate (milligram) | –  | 54.2 ± 5.9  | 45.1 ± 5.6  | 36.4         | 0.000        |
| Dosage of remifentanil (microgram) | –  | 915.7 ± 41.2 | 897.9 ± 38.0 | 2.95         | 0.0911       |
| Time to spontaneous respiration (minute) | 16.5 ± 1.7  | 17.2 ± 2.4  | 19.1 ± 2.5†  | 10.84        | 0.000        |
| Time to recovery (minute) | 18.9 ± 2.1  | 19.7 ± 2.7  | 23.4 ± 2.6†  | 30.24        | 0.000        |
| Tracheal extubation time (minute) | 20.6 ± 2.4  | 21.5 ± 2.9  | 26.4 ± 2.5†  | 44.48        | 0.000        |
| PACU stay time (minute) | 59.9 ± 6.2  | 58.4 ± 5.4  | 62.1 ± 9.4  | 1.93         | 0.1511       |

Table 10. Clinical characteristics in long operation time groups. The clinical characteristics in long operation time groups are shown in this table. The duration of surgery were similar among the three groups. The dosage of remifentanil and etomidate were significantly lower in ERD2 group compared with ER2 group \((P<0.05)\). The time to spontaneous respiration, tracheal extubation time, the time to recovery and the PACU stay time were longer in group ERD2 compared with group ER2 \((P<0.05)\), (in this table). Values are mean ± SD. PR Propofol-remifentanil, ER Etomidate-remifentanil, ERD Etomidate-remifentanil and dexmedetomidine, PACU postanesthesia care unit. ∗\(p<0.05\) vs. PR2 group; †\(p<0.05\) vs. ER2 group.

| Clinical characteristics | PR2 \(n=32\) | ER2 \(n=31\) | ERD2 \(n=28\) | \(F\) values | \(P\) values |
|--------------------------|--------------|--------------|---------------|--------------|--------------|
| Duration of surgery (minute) | 105.5 ± 20.6 | 102.9 ± 16.2 | 104.5 ± 19.7 | 0.54         | 0.5831       |
| Dosage of etomidate (milligram) | –  | 95.0 ± 10.1  | 74.4 ± 7.1†  | 81.23        | 0.000        |
| Dosage of remifentanil (microgram) | –  | 1676.5 ± 188.6 | 1452.9 ± 132.0 | 25.55        | 0.000        |
| Time to spontaneous respiration (minute) | 17.4 ± 2.1  | 18.1 ± 2.7  | 19.9 ± 2.6†  | 7.91         | 0.0007       |
| Time to recovery (minute) | 19.8 ± 2.1  | 20.3 ± 3.0  | 25.6 ± 2.8†  | 41.61        | 0.000        |
| Tracheal extubation time (minute) | 21.3 ± 2.1  | 22.4 ± 3.2  | 27.7 ± 3.4†  | 38.68        | 0.000        |
| PACU stay time (minute) | 69.4 ± 7.1  | 71.7 ± 9.9  | 77.7 ± 11.4† | 6.01         | 0.0036       |
Dexmedetomidine is a highly specific α₂-adrenoceptor agonist with short half-life period (about 2 h). It has a dose-dependent sedative and analgesic effect, and has no adverse effect on respiration. The application of dexmedetomidine (0.5 g/kg) in pediatric patients anesthetized with sevoflurane could decrease the heart rate of children, but there were no significant changes in SBP, DBP or PETCO₂. It was shown that dexmedetomidine as an adjunct for inhalation anesthetics could effectively maintain the stability of circulation and respiration during surgery. In recent clinical trials, the effect of dexmedetomidine on the requirement for propofol and remifentanil in total intravenous anesthesia was studied. It was found that the administration of dexmedetomidine significantly decreased both the requirements for propofol and remifentanil during anesthesia induction and the dosage of propofol administered during surgery. In this study, when dexmedetomidine was added to intravenous anesthesia with etomidate, the intraproductive dosages of etomidate were reduced by 17% and 22% in the short time surgery group and long time surgery group respectively, and the dosage of remifentanil was reduced by 13% in long time surgery group, which was consistent with the above research results.

In this study, the administration of dexmedetomidine not only reduced the etomidate requirements for total intravenous anesthesia in elderly patients, but also attenuated and shortened the inhibitory effect of etomidate on adrenocortical function in elderly patients. This is mainly because the inhibition effects of etomidate on adrenal cortex function were dose-dependent, the administration of dexmedetomidine significantly reduced the requirement for etomidate, and with the reduction of etomidate dose, the inhibitory effect of etomidate on adrenal cortex was correspondingly attenuated in this study. In vitro studies showed that dexmedetomidine combined with etomidate had a stronger inhibitory effect on human adrenocortical cells than etomidate alone. However, some scholars studied the effect of dexmedetomidine and etomidate on adrenocortical function in children and found that 3 h after induction of anesthesia, the serum cortisol concentration of patients in the etomidate group was the lowest, while there was no difference between dexmedetomidine group and the control group, indicating that dexmedetomidine had little or no effect on adrenocortical function. The researches above showed that the inhibitory effect of dexmedetomidine on adrenal function is controversial currently. The inhibitory effect of dexmedetomidine on adrenocortical function in elderly patients was not studied in our study, so the effect of dexmedetomidine on adrenocortical function in elderly patients is still unknown.

In clinic, the induction of anesthesia with propofol often leads to the decrease of arterial blood pressure. Due to the degradation of organ function and the declination of physiological function, it is easier to induce hypotension in elderly patients anesthetized with propofol. The blood pressure was decreased significantly compared to the baseline in patients by using propofol and etomidate for anesthesia induction, and the decrease was greater in the propofol group compared to etomidate group. In this study, 5 min after induction of anesthesia with propofol, the systolic pressure, diastolic pressure and heart rate were decreased by 23.5%, 28.4% and 13%, respectively. This was mainly attributed to propofol reducing cardiac output and systemic vascular resistance, and inhibiting baroreceptor reflex. However, in the etomidate group, systolic blood pressure was decreased by 14.6%, diastolic blood pressure was decreased by 12% and heart rate was decreased by 14% 5 min after induction of anesthesia. Although there was no difference in the decrease of heart rate, the decrease of systolic and diastolic blood pressure were more gently in etomidate group compared to propofol group. Meanwhile, the blood pressure of patients during surgery was significantly lower in propofol group compared to etomidate group. It was suggested that the hemodynamic stability in the elderly patients could be better maintained with etomidate anesthesia.

Dexmedetomidine could maintain intraoperative hemodynamic stability by inhibiting sympathetic nervous system and attenuating the stress response. Davy A et al. reported about 42% patients who were administered with dexmedetomidine developed various degree hypotension and bradycardia. Dexmedetomidine could decrease the heart rate and blood pressure in a dose-dependent manner. A clinical study found that low dose dexmedetomidine (0.5 μg·kg⁻¹·h⁻¹) can effectively reduce the requirement of propofol and maintain the intraoperative hemodynamics of patients undergoing laparoscopic cholecystectomy. Josephine et al. pointed out in their review on hemodynamic response of high- and low-dose dexmedetomidine that compared with high-dose dexmedetomidine, low-dose dexmedetomidine had better hemodynamic stability and shorter recovery time. In our study, there was no difference in systolic and diastolic blood pressure between etomidate alone group and combined dexmedetomidine group at 5 min after anesthesia induction, the beginning of surgery and during surgery. But the addition of dexmedetomidine could decrease the intraoperative heart rate more significantly than etomidate alone, and no patient developed bradycardia. It showed that although the combination of dexmedetomidine (0.4 μg/kg/h) could decrease intraoperative heart rate, but had little effect on the intraoperative blood pressure in elderly patients undergoing general anesthesia, which was consistent with the results of recent studies.

There was little correlation between intraoperative dexmedetomidine and the recovery time after propofol anesthesia in common outpatient procedures, and the potential dose relationship was that the administration of per μg/kg dexmedetomidine would increase recovery time for about 15 min. In present study, when etomidate was combined with dexmedetomidine, the time to spontaneous respiration, time to recovery and tracheal extubation time were prolonged. However, intraoperative intravenous infusion of dexmedetomidine (0.4 μg/kg/h) did not affect postoperative anesthesia recovery in patients undergoing thoracic surgery, or provided faster recovery in patients undergoing tympanoplasty surgery. It was suggested that the administration of dexmedetomidine in long-term surgery rather than short-term surgery could provide faster recovery.

There are limitations in this study. Firstly, we didn’t design a trial to identify the effect of dexmedetomidine alone on adrenocortical function in elderly patients. It is not clear whether the administration of dexmedetomidine suppress the adrenocortical function. Secondly, an enzymatic block of 11β-hydroxylase was demonstrated in a patient who received a prolonged infusion of etomidate. We didn’t observe the enzymatic block.
of 11-b-hydroxylation both in short and long time surgery groups in this study, and the effects of intravenous infusion of dexmedetomidine combined with etomidate on the enzymatic block of 11-b-hydroxylase at different times need to be further studied. Thirdly, the principal adrenocortical products are cortisol, aldosterone and dehydroepiandrosterone sulphate. We only observed changes in plasma concentrations of cortisol and adrenocortisol in present study, but the effect of administration of etomidate combined with dexmedetomidine on adrenocortical secretion of aldosterone was not clear. Fourthly, in our study, the surgery time of urethral holmium laser lithotripsy was within 2.5 h, and the effect of etomidate combined with dexmedetomidine infusion for more than 2.5 h on adrenocortical function was unclear. We will apply the combination of dexmedetomidine and etomidate in long-term surgery to observe the changes of adrenal cortex function of elderly patients in future studies. Finally, the sample size of our study is too small. If this study had been performed on a larger sample size, there would probably have been more significant results in terms of the dose- and time-dependent effects of dexmedetomidine on etomidate-induced inhibition of adrenal cortical function.

In conclusion, the inhibitory effect of etomidate on adrenocortical function in elderly patients was prolonged with the duration of intravenous anesthesia with etomidate. The administration of dexmedetomidine combined with etomidate can attenuate the inhibition of etomidate on adrenocortical function in elderly patients and maintain intraoperative hemodynamic stability.

Received: 19 June 2021; Accepted: 13 July 2022
Published online: 19 July 2022

References
1. Sunshine, J. E. et al. Etomidate, adrenal function, and mortality in critically ill patients. Respir. Care 58(4), 639–646. https://doi.org/10.4187/respcare.01956 (2013).
2. Mozanski, M., Tomaszewski, D., Rybczki, Z., Bejm, J. & Balkota, M. Etomidate, but not thiopental, decreases serum cortisol concentration in morbidly obese patients: A randomized controlled trial. Anaesthesiol. Intens. Ther. 48(1), 7–12. https://doi.org/10.5603/ait.2016.0002 (2016).
3. Dutta, A. et al. The effect of dexmedetomidine on propofol requirements during anesthesia administered by bispectral index-guided closed-loop anesthesia delivery system: A randomized controlled study. Anesth. Analg. 129(1), 84–91. https://doi.org/10.1213/ane.0000000000003470 (2019).
4. Deutsch, E. & Tobias, J. D. Hemodynamic and respiratory changes following dexmedetomidine administration during general anesthesia: sevoflurane vs desflurane. Paediatr. Anaesth. 17(5), 438–444. https://doi.org/10.1111/j.1460-9592.2006.02139.x (2007).
5. Moussa, S. A. & Alsobky, H. A. E. Efficacy and effect of TIVA with propofol or dexmedetomidine versus sevoflurane without muscle relaxant during repair of the brachial plexus. Egypt. J. Anaesth. 29, 31–40. https://doi.org/10.1016/j.eja.2012.08.001 (2013).
6. Ng, S. M., Ogundiya, A., Didi, M. & Turner, M. A. Adrenal function of extremely premature infants in the first 5 days after birth. Eur. J. Clin. Pharmacol. 72(4), 363–365. https://doi.org/10.1515/ejcp-2018-0417 (2019).
7. Meynec Kôskal, G. et al. The effect of single dose etomidate during emergency intubation on hemodynamics and adrenal cortex. Ulus Travma Acil Cerrahi Derg. 21(5), 358–365. https://doi.org/10.5305/rtj.2015.06325 (2015).
8. Fengler, B. T. Should etomidate be used for rapid-sequence intubation induction in critically ill septic patients?. Am. J. Emerg. Med. 26(2), 229–232. https://doi.org/10.1016/j.ajem.2008.04.009 (2008).
9. Ge, R., Pejo, E., Cotten, J. F. & Raines, E. Adrenocortical suppression and recovery after continuous hypnographic infusion: Etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate. Crit. Care. 17(1), R20. https://doi.org/10.1186/cc12494 (2013).
10. Prakash, M. V. S. S., Gnanasekar, R., Sakthirajan, P. & Adole, P. S. A comparative study of two infusion doses of etomidate for induction vs standard induction dose of etomidate. Eur. J. Clin. Pharmacol. 75(7), 889–894. https://doi.org/10.1007/s00228-019-02681-6 (2019).
11. Wang, N., Wang, X. H., Lu, J. & Zhang, J. Y. The effect of repeated etomidate anesthesia on adrenocortical function during a course of electroconvulsive therapy. J. ECT. 27(4), 281–285. https://doi.org/10.1097/yct.0b013e3182182be0 (2011).
12. Poorzamany Nejat Kermany, M., Dahi, M., Yamin Sharif, R. & Radpay, B. Comparison of the effects of dexmedetomidine and remifentanil on cognition state after cataract surgery. Anesth. Pain Med. 6(3), e33448. https://doi.org/10.5505/tjtes.2015.06325 (2015).
13. Le Guen, M. et al. Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-loop anesthesia: A double-blind, placebo-controlled trial. Anesth. Analg. 115(5), 946–955. https://doi.org/10.1213/ane.0000000000001885 (2014).
14. Malapeiro, R. J., Zaccagnino, M. P., Brouvan, E. Y., Kaye, A. D. & Urman, R. D. Etomidate derivatives: Novel pharmaceutical agents in anesthesia. J. Anesth. Clin. Pharmacol. 33(4), 429–431. https://doi.org/10.4103/0970-9185.222521 (2017).
15. Gu, J., Zhang, M., Cai, M. & Liu, J. Combined use of etomidate and dexmedetomidine produces an additive effect in inhibiting the secretion of human adrenocortical hormones. Med. Sci. Monit. 21, 3528–3535. https://doi.org/10.12659/MSM.894728 (2015).
16. Gu, H., Zhang, M., Cai, M. & Liu, J. Comparison of adrenal suppression between etomidate and dexmedetomidine in children with congenital heart disease. Med. Sci. Monit. 21, 1569–1576. https://doi.org/10.12659/MSM.893410 (2015).
17. Hu, B., Zhong, Y. & Zhou, X. Propofol vs. thiopental in hypotension after GA induction. J. Anesth. 33(6), 705. https://doi.org/10.1007/s00549-019-02686-6 (2019).
18. Chiu, C. L., Tew, G. P. & Wang, C. Y. The effect of prophylactic metaraminol on systemic hypotension caused by induction of anaesthesia with propofol in patients over 55 years old. Anaesthesia 56(9), 893–897. https://doi.org/10.1111/1365-2442.2001.02059-x.4 (2001).
19. Iļāņa, O., Taņš, N., Ķūķiņš, A., Hanci, V. & Yurtlu, B. S. Haemodynamic responses to tracheal intubation using propofol, etomidate and etomidate-propofol combination in anaesthesia induction. J. Cardiovasc. Transl. 7(4), 134–140. https://doi.org/10.15171/jcvtr.2015.30 (2015).
20. Li, Z., Li, C. & Zhang, M. Effect of dexmedetomidine on hemodynamics in patients undergoing hysterectomy: A meta-analysis and systematic review. J. Int. Med. Res. 49(6), 300065211039809. https://doi.org/10.1177/0300065211039809 (2021).
21. Davy, A., Fessler, J., Fischler, M. & Guen, L. E. Dexmedetomidine and general anesthesia: A narrative literature review of its major indications for use in adults undergoing non-cardiac surgery. Minerva Anestesiol. 83(12), 1294–1308. https://doi.org/10.23736/S0375-9393.17.12040-7 (2017).
22. Ren, J., Li, C., Ma, S., Wu, J. & Yang, Y. Impact of dexmedetomidine on hemodynamics in rabbits. Acta Circ. Bras. 33(4), 314–323. https://doi.org/10.1590/1983-68502018004000003 (2018).
23. Kalaskar, V. P., Ruparel, D. H. & Waloode, R. P. Effects of dexmedetomidine infusion in low dose on dose reduction of propofol, intraoperative hemodynamics, and postoperative analgesia in patients undergoing laparoscopic cholecystectomy. Anesth. Essays Res. 15(4), 391–394. https://doi.org/10.4103/aer.aer_123_21 (2021).
24. Josephine, C., Shariffuddin, I. I., Chaw, S. H., Ng, K. W. S. & Ng, K. T. Hemodynamic response of high- and low-dose dexmedetomidine of pediatric in general anesthesia: A systematic review and meta-analysis of randomized controlled trials. *Asian J. Anesthesiol.* 59(1), 7–21. https://doi.org/10.6859/aia.202103_59(1).0002 (2021).

25. Ghodki, P. S. & Shetye, N. N. Pretreatment with dexmedetomidine and magnesium sulphate in prevention of etomidate induced myoclonus: A double blinded randomised controlled trial. *Indian J. Anaesth.* 65(5), 404–407. https://doi.org/10.4103/ija.IJA_1309_20 (2021).

26. West, N., Gorges, M., Poznikoff, A., Whyte, S. & Malherbe, S. Association of dexmedetomidine with recovery room and hospital discharge times: A retrospective cohort analysis. *Paediatr. Anaesth.* 31(11), 1170–1178. https://doi.org/10.1111/pan.14257 (2021).

27. Zhang, L. Y., Zhang, Y. H., Shen, J. & Luo, Y. Effects of dexmedetomidine on post-operative recovery and mental status in patients receiving robotic-assisted thoracic surgery. *Ann. Palliat. Med.* 8(4), 469–475. https://doi.org/10.21037/apm.2019.08.09 (2019).

28. Kosucu, M., Tugcugil, E., Cobanoglu, B. & Arslan, E. Evaluation of the perioperative effects of dexmedetomidine on tympanoplasty operations. *Am. J. Otolaryngol.* 41(6), 102619. https://doi.org/10.1016/j.amjoto.2020.102619 (2020).

29. Wagner, R. L. & White, P. F. Etomidate inhibits adrenocortical function in surgical patients. *Anesthesiology* 61(6), 647–651. https://doi.org/10.1097/00000542-198412000-00003 (1984).

30. Sharp, A. M., Handelsman, D. J., Ristuccia, R. M. & Turtle, J. R. Dexamethasone suppression of adrenocortical function. *Clin. Chem.* 28(6), 1333–1334. https://doi.org/10.1093/clinchem/28.6.1333 (1982).

**Acknowledgements**

The authors thank the participants for their enthusiastic collaboration, the urological surgeons and nurses assisted in specimen collection, and the laboratory physician helped to test for plasma concentration of cortisol and ACTH.

**Author contributions**

F.J.W. wrote the main manuscript text. F.J.W, Y.Z. and S.S.Z. analysed and interpreted the data. L.Y.G. performed clinical data acquisition. F.J.W. and J.B.L. designed and supervised the origin PopCol study, J.B.L. and N.W. processed all the samples and detected the Plasma concentration of ACTH and cortisol. All authors contributed to discuss the results and to research directions. All authors reviewed the manuscript and approved the manuscript.

**Funding**

This study was funded, in part, by the foundation of Sichuan Medical Association (EH-MN14-06). None of the funding sources played a role in the design, collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to F.W.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2022